CSIMarket Company Name, Ticker, Industry, else..
 
Kyverna Therapeutics Inc   (NASDAQ: KYTX)
 
Price: $6.5200 $-0.28 -4.118%
Day's High: $6.909999847412109 Week Perf: -4.26 %
Day's Low: $ 6.51 30 Day Perf: -21.92 %
Volume (M): 785,456 52 Wk High: $ 13.67
Volume (M$): $ 0 52 Wk Avg: $8.13
Open: $6.80 52 Wk Low: $5.30



 Market Capitalization (Millions $) 397
 Shares Outstanding (Millions) 61
 Employees 130
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -153
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 1

Business Description


The company conducts research, development, and clinical testing of product candidates for the treatment of specific diseases and conditions. Its activities include preclinical studies, clinical trials, regulatory approvals, manufacturing, commercialization, intellectual property management, and strategic collaborations.


   Company Address: 5980 Horton St. Emeryville 94608 CA
   Company Phone Number: 925-2492   Stock Exchange / Ticker: NASDAQ KYTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IMMX   -12.56%    
• View Complete Report
   



Clinical Study

Kyverna Therapeutics KYV-101 A Breakthrough in Myasthenia Gravis Treatment Poised to Redefine the Future,

Published Wed, Oct 29 2025 2:33 PM UTC

Breaking New Ground in Myasthenia Gravis Treatment: Positive Phase 2 Data from KYV-101 Study Marks a Milestone for Kyverna Therapeutics Compelling Results Set New Clinical Standard in Generalized Myasthenia Gravis (gMG), Raising Confidence for Upcoming Phase 3 Trial Kyverna Therapeutics Inc. (NASDAQ: KYTX) has recently announced encouraging interim results from its KYSA-6 P...
Clinical Study

Kyverna Therapeutics Unveils KYV-101 A Potential Game-Changer in Multiple Sclerosis Treatment,

Published Wed, Sep 24 2025 3:01 PM UTC

Promising Advances in Multiple Sclerosis Treatment: Kyverna Therapeutics Highlights KYV-101 at ECTRIMSKyverna Therapeutics is generating significant interest in the field of multiple sclerosis (MS) research with their recent report on KYV-101, an innovative CAR T-cell therapy currently undergoing investigator-initiated trials. The data, set to be presented at the upcoming E...
Clinical Study

Kyverna Therapeutics Advances CAR T Therapy for Myasthenia Gravis with Phase 3 Trial of KYV-101,

Published Thu, Aug 28 2025 12:09 PM UTC

Advanced CAR T Therapy for Myasthenia Gravis: Kyverna Therapeutics Unveils Promising Developments Kyverna Therapeutics, a leader in cell therapy development, recently underscored the progress of its Neuroimmunology CAR T franchise during a virtual Key Opinion Leader (KOL) event. The highlight of the presentation was the innovative KYV-101 therapy, which is currently advancin...
Announcement

Investors Urged to Act Legal Counsel Needed Before February Deadline for Kyverna Therapeutics Securities Class Action

Published Fri, Jan 31 2025 10:23 PM UTC

In an urgent alert, the Rosen Law Firm, a highly recognized entity in the field of investor rights, has prompted investors of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) to secure legal counsel ahead of a critical February 7, 2025 deadline concerning a securities class action. This action pertains to investors who acquired common shares during the company’s initial public of...
Announcement

Class Action Looms Over Kyverna Therapeutics, Inc. with February Deadline for Lead Plaintiffs

Published Mon, Dec 30 2024 6:25 PM UTC

In a significant development for stakeholders of Kyverna Therapeutics, Inc. investors are being alerted to an impending class action lawsuit against the company. Levi & Korsinsky, LLP, a prominent securities litigation firm, has issued a notice to investors regarding the class action lawsuit, urging them to be aware of a critical deadline. The legal proceedings come with a l...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 2.4
PEG (TTM) -

Financial Strength Current
Quick Ratio 16.1
Working Capital Ratio 16.41
Leverage Ratio (MRQ) 0.33
Total Debt to Equity 0.15
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.99 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 6.03 $
Book Value 2.72 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,174,138
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.